Predictive value of remnant cholesterol for left ventricular hypertrophy and prognosis in hypertensive patients with heart failure: a prospective study

Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patient...

Full description

Saved in:
Bibliographic Details
Published inLipids in health and disease Vol. 23; no. 1; pp. 294 - 9
Main Authors Wang, Zeyu, Zhu, Zhaoxin, Shen, Jianying, Zhang, Yan, Wang, Ting, Xu, Yawei, Jiang, Dongyang, Liu, Weijing
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 12.09.2024
BioMed Central
BMC
Subjects
Online AccessGet full text
ISSN1476-511X
1476-511X
DOI10.1186/s12944-024-02282-y

Cover

Loading…
Abstract Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients' prognoses. Six hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62-2.26 vs. HR: 1.75, 95% CI: 1.43-2.16, P < 0.001). RC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality. NCT03727828, 21 Oct 2018.
AbstractList Abstract Background and Aim Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients’ prognoses. Methods and results Six hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62–2.26 vs. HR: 1.75, 95% CI: 1.43–2.16, P < 0.001). Conclusions RC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality. Trial registration NCT 03727828, 21 Oct 2018.
Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients' prognoses. Six hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62-2.26 vs. HR: 1.75, 95% CI: 1.43-2.16, P < 0.001). RC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality.
Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients' prognoses. Six hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62-2.26 vs. HR: 1.75, 95% CI: 1.43-2.16, P < 0.001). RC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality. NCT03727828, 21 Oct 2018.
Background and Aim Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients' prognoses. Methods and results Six hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62-2.26 vs. HR: 1.75, 95% CI: 1.43-2.16, P < 0.001). Conclusions RC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality. Trial registration NCT 03727828, 21 Oct 2018. Keywords: Remnant cholesterol (RC), Hypertension, Heart failure (HF), Left ventricular hypertrophy (LVH), Prognosis
Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients' prognoses.BACKGROUND AND AIMRemnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients' prognoses.Six hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62-2.26 vs. HR: 1.75, 95% CI: 1.43-2.16, P < 0.001).METHODS AND RESULTSSix hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62-2.26 vs. HR: 1.75, 95% CI: 1.43-2.16, P < 0.001).RC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality.CONCLUSIONSRC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality.NCT03727828, 21 Oct 2018.TRIAL REGISTRATIONNCT03727828, 21 Oct 2018.
ArticleNumber 294
Audience Academic
Author Xu, Yawei
Wang, Ting
Liu, Weijing
Wang, Zeyu
Jiang, Dongyang
Shen, Jianying
Zhang, Yan
Zhu, Zhaoxin
Author_xml – sequence: 1
  givenname: Zeyu
  surname: Wang
  fullname: Wang, Zeyu
– sequence: 2
  givenname: Zhaoxin
  surname: Zhu
  fullname: Zhu, Zhaoxin
– sequence: 3
  givenname: Jianying
  surname: Shen
  fullname: Shen, Jianying
– sequence: 4
  givenname: Yan
  surname: Zhang
  fullname: Zhang, Yan
– sequence: 5
  givenname: Ting
  surname: Wang
  fullname: Wang, Ting
– sequence: 6
  givenname: Yawei
  surname: Xu
  fullname: Xu, Yawei
– sequence: 7
  givenname: Dongyang
  surname: Jiang
  fullname: Jiang, Dongyang
– sequence: 8
  givenname: Weijing
  surname: Liu
  fullname: Liu, Weijing
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39267042$$D View this record in MEDLINE/PubMed
BookMark eNp9kt2K1TAUhYuMOD_6Al5IwBtvOiZpmjbeyDD4MzCgFwrehTTZOc3Qk9SkPcN5El_XdHocZkQkhJSdtT52d9ZpceSDh6J4SfA5IS1_mwgVjJWYLpu2tNw_KU4Ia3hZE_Lj6MH3cXGa0g3GFDecPyuOK0F5gxk9KX59jWCcntwO0E4NM6BgUYStV35Cug8DpAliGJANEQ1gJ7QDP0Wn50FF1O9HiFMMY79Hyhs0xrDxIbmEnD9cgk8Le1STy8aEbt3Uox5UnJBVbpgjvENqMaYR1jbSNJv98-KpVUOCF4fzrPj-8cO3y8_l9ZdPV5cX16WuKz6VlhqrFNOEE0YbXWOr69aKphNCdFWtOGeGdUTUjIjKdFR1QFsuFKE17rQW1VlxtXJNUDdyjG6r4l4G5eRdIcSNzK06PYAE20BbUQVMGcag6lqmjYGGmVy0Nc-s9ytrnLstGL0MSg2PoI9vvOvlJuwkIZUgLaOZ8OZAiOHnnEcvty5pGAblIcxJVgQzXAmBSZa-XqUblXtz3oaM1ItcXrS4rTmuyAI8_4cqLwNbp3OcrMv1R4ZXD__hvvk_ickCugp0frIUwd5LCJZLLOUaS5ljKe9iKffZ1P5l0m7KiQjLHNzwP-tv46TsBQ
CitedBy_id crossref_primary_10_1016_j_atherosclerosis_2025_119129
Cites_doi 10.1016/j.pcad.2019.11.009
10.1016/j.cca.2018.12.014
10.1016/j.jacc.2020.10.008
10.1016/j.ahj.2008.07.004
10.7326/AITC201712050
10.3399/BJGP.2023.0328
10.1186/s12933-022-01554-0
10.1016/j.cjca.2017.07.015
10.1016/j.pcad.2014.05.003
10.1016/j.jacc.2020.01.014
10.1093/eurheartj/eht133
10.1093/eurheartj/ehab293
10.1097/MOL.0000000000000330
10.1186/s12933-020-01076-7
10.1111/jch.12282
10.1111/joim.13059
10.1016/j.jacc.2020.09.583
10.1186/s12933-016-0454-x
10.1093/eurheartj/ehab368
10.1093/eurheartj/ehab705
10.1161/HYPERTENSIONAHA.108.114439
10.1093/eurheartj/ehy339
10.1093/ehjqcco/qcad030
10.3389/fcvm.2023.1063562
10.1161/CIRCIMAGING.123.015589
10.1161/CIRCIMAGING.115.004426
10.1530/EC-23-0476
10.3390/jcm10153388
10.1007/s00125-023-06016-0
10.3389/fcvm.2022.993097
10.1016/j.healun.2009.04.026
10.3389/fcvm.2022.938647
10.1016/j.numecd.2023.02.009
10.1186/s12933-017-0519-5
10.1186/s12933-018-0773-1
ContentType Journal Article
Copyright 2024. The Author(s).
COPYRIGHT 2024 BioMed Central Ltd.
The Author(s) 2024 2024
Copyright_xml – notice: 2024. The Author(s).
– notice: COPYRIGHT 2024 BioMed Central Ltd.
– notice: The Author(s) 2024 2024
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1186/s12944-024-02282-y
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1476-511X
EndPage 9
ExternalDocumentID oai_doaj_org_article_ef7e832ae4ad44e3b84cdde74d32af56
PMC11391842
A808560312
39267042
10_1186_s12944_024_02282_y
Genre Journal Article
GeographicLocations China
Canada
Taiwan
GeographicLocations_xml – name: China
– name: Canada
– name: Taiwan
GrantInformation_xml – fundername: Science and Technology Commission of Shanghai Municipality
  grantid: No. 22Y11910000
GroupedDBID ---
0R~
29L
2WC
53G
5GY
5VS
7X7
88E
8FE
8FH
8FI
8FJ
A8Z
AAFWJ
AAHBH
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IAO
IGS
IHR
INH
INR
ITC
KQ8
LK8
M1P
M48
M7P
M~E
O5R
O5S
OK1
OVT
P2P
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
PMFND
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c536t-f2dfaa4c161427c50fc58f97b999b35a664d4b1954193db2abe2869a1250bcc93
IEDL.DBID M48
ISSN 1476-511X
IngestDate Wed Aug 27 01:20:31 EDT 2025
Thu Aug 21 18:34:22 EDT 2025
Thu Jul 10 22:25:58 EDT 2025
Tue Jun 17 22:03:35 EDT 2025
Tue Jun 10 21:04:29 EDT 2025
Mon Jul 21 06:03:34 EDT 2025
Thu Apr 24 23:09:17 EDT 2025
Tue Jul 01 00:23:23 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Hypertension
Prognosis
Left ventricular hypertrophy (LVH)
Remnant cholesterol (RC)
Heart failure (HF)
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c536t-f2dfaa4c161427c50fc58f97b999b35a664d4b1954193db2abe2869a1250bcc93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/ef7e832ae4ad44e3b84cdde74d32af56
PMID 39267042
PQID 3104039901
PQPubID 23479
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_ef7e832ae4ad44e3b84cdde74d32af56
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11391842
proquest_miscellaneous_3104039901
gale_infotracmisc_A808560312
gale_infotracacademiconefile_A808560312
pubmed_primary_39267042
crossref_primary_10_1186_s12944_024_02282_y
crossref_citationtrail_10_1186_s12944_024_02282_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-09-12
PublicationDateYYYYMMDD 2024-09-12
PublicationDate_xml – month: 09
  year: 2024
  text: 2024-09-12
  day: 12
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Lipids in health and disease
PublicationTitleAlternate Lipids Health Dis
PublicationYear 2024
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References J Park (2282_CR33) 2017; 16
B Williams (2282_CR11) 2018; 39
PG Jørgensen (2282_CR9) 2016; 15
S Gao (2282_CR14) 2017; 33
A Varbo (2282_CR19) 2021; 42
J Borén (2282_CR18) 2016; 27
MR Mehra (2282_CR6) 2009; 28
ER Rietzschel (2282_CR13) 2008; 52
L Zhao (2282_CR31) 2023; 10
2282_CR17
J Liu (2282_CR20) 2022; 9
TB Horwich (2282_CR5) 2008; 156
L Kopin (2282_CR3) 2017; 167
JM de Hartog-Keyzer (2282_CR30) 2024; 74
J Deng (2282_CR24) 2023; 33
G Su (2282_CR16) 2014; 16
CJ Lavie (2282_CR2) 2014; 57
N Aung (2282_CR4) 2020; 76
X Hu (2282_CR28) 2022; 21
A Langsted (2282_CR23) 2020; 288
BN Wadström (2282_CR27) 2022; 43
S Ida (2282_CR32) 2018; 17
R Wang (2282_CR15) 2023; 9
TA McDonagh (2282_CR12) 2021; 42
2282_CR21
O Castañer (2282_CR26) 2020; 76
H Liu (2282_CR8) 2022; 9
EY Choi (2282_CR29) 2013; 34
2282_CR25
H Tada (2282_CR7) 2019; 490
X Xu (2282_CR10) 2023; 16
SP Murphy (2282_CR22) 2020; 75
M Yildiz (2282_CR1) 2020; 63
YX Cao (2282_CR34) 2020; 19
BN Wadström (2282_CR35) 2023; 66
References_xml – volume: 63
  start-page: 10
  issue: 1
  year: 2020
  ident: 2282_CR1
  publication-title: Prog Cardiovasc Dis
  doi: 10.1016/j.pcad.2019.11.009
– volume: 490
  start-page: 1
  year: 2019
  ident: 2282_CR7
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2018.12.014
– volume: 76
  start-page: 2712
  issue: 23
  year: 2020
  ident: 2282_CR26
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2020.10.008
– volume: 156
  start-page: 1170
  issue: 6
  year: 2008
  ident: 2282_CR5
  publication-title: Am Heart J
  doi: 10.1016/j.ahj.2008.07.004
– volume: 167
  start-page: Itc81
  issue: 11
  year: 2017
  ident: 2282_CR3
  publication-title: Ann Intern Med
  doi: 10.7326/AITC201712050
– volume: 74
  start-page: e219
  issue: 741
  year: 2024
  ident: 2282_CR30
  publication-title: Br J Gen Pract
  doi: 10.3399/BJGP.2023.0328
– volume: 21
  start-page: 117
  issue: 1
  year: 2022
  ident: 2282_CR28
  publication-title: Cardiovasc Diabetol
  doi: 10.1186/s12933-022-01554-0
– volume: 33
  start-page: 1624
  issue: 12
  year: 2017
  ident: 2282_CR14
  publication-title: Can J Cardiol
  doi: 10.1016/j.cjca.2017.07.015
– volume: 57
  start-page: 3
  issue: 1
  year: 2014
  ident: 2282_CR2
  publication-title: Prog Cardiovasc Dis
  doi: 10.1016/j.pcad.2014.05.003
– volume: 75
  start-page: 1324
  issue: 11
  year: 2020
  ident: 2282_CR22
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2020.01.014
– volume: 34
  start-page: 2354
  issue: 30
  year: 2013
  ident: 2282_CR29
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/eht133
– volume: 42
  start-page: 4833
  issue: 47
  year: 2021
  ident: 2282_CR19
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehab293
– volume: 27
  start-page: 473
  issue: 5
  year: 2016
  ident: 2282_CR18
  publication-title: Curr Opin Lipidol
  doi: 10.1097/MOL.0000000000000330
– volume: 19
  start-page: 104
  issue: 1
  year: 2020
  ident: 2282_CR34
  publication-title: Cardiovasc Diabetol
  doi: 10.1186/s12933-020-01076-7
– volume: 16
  start-page: 192
  issue: 3
  year: 2014
  ident: 2282_CR16
  publication-title: J Clin Hypertens (Greenwich)
  doi: 10.1111/jch.12282
– volume: 288
  start-page: 116
  issue: 1
  year: 2020
  ident: 2282_CR23
  publication-title: J Intern Med
  doi: 10.1111/joim.13059
– volume: 76
  start-page: 2477
  issue: 21
  year: 2020
  ident: 2282_CR4
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2020.09.583
– volume: 15
  start-page: 137
  issue: 1
  year: 2016
  ident: 2282_CR9
  publication-title: Cardiovasc Diabetol
  doi: 10.1186/s12933-016-0454-x
– volume: 42
  start-page: 3599
  issue: 36
  year: 2021
  ident: 2282_CR12
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehab368
– volume: 43
  start-page: 3258
  issue: 34
  year: 2022
  ident: 2282_CR27
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehab705
– volume: 52
  start-page: 535
  issue: 3
  year: 2008
  ident: 2282_CR13
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.108.114439
– volume: 39
  start-page: 3021
  issue: 33
  year: 2018
  ident: 2282_CR11
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehy339
– volume: 9
  start-page: 537
  issue: 5
  year: 2023
  ident: 2282_CR15
  publication-title: Eur Heart J Qual Care Clin Outcomes
  doi: 10.1093/ehjqcco/qcad030
– volume: 10
  start-page: 1063562
  year: 2023
  ident: 2282_CR31
  publication-title: Front Cardiovasc Med
  doi: 10.3389/fcvm.2023.1063562
– volume: 16
  start-page: e015589
  issue: 11
  year: 2023
  ident: 2282_CR10
  publication-title: Circ Cardiovasc Imaging
  doi: 10.1161/CIRCIMAGING.123.015589
– ident: 2282_CR21
  doi: 10.1161/CIRCIMAGING.115.004426
– ident: 2282_CR17
  doi: 10.1530/EC-23-0476
– ident: 2282_CR25
  doi: 10.3390/jcm10153388
– volume: 66
  start-page: 2238
  issue: 12
  year: 2023
  ident: 2282_CR35
  publication-title: Diabetologia
  doi: 10.1007/s00125-023-06016-0
– volume: 9
  start-page: 993097
  year: 2022
  ident: 2282_CR20
  publication-title: Front Cardiovasc Med
  doi: 10.3389/fcvm.2022.993097
– volume: 28
  start-page: 876
  issue: 9
  year: 2009
  ident: 2282_CR6
  publication-title: J Heart Lung Transpl
  doi: 10.1016/j.healun.2009.04.026
– volume: 9
  start-page: 938647
  year: 2022
  ident: 2282_CR8
  publication-title: Front Cardiovasc Med
  doi: 10.3389/fcvm.2022.938647
– volume: 33
  start-page: 1049
  issue: 5
  year: 2023
  ident: 2282_CR24
  publication-title: Nutr Metab Cardiovasc Dis
  doi: 10.1016/j.numecd.2023.02.009
– volume: 16
  start-page: 36
  issue: 1
  year: 2017
  ident: 2282_CR33
  publication-title: Cardiovasc Diabetol
  doi: 10.1186/s12933-017-0519-5
– volume: 17
  start-page: 129
  issue: 1
  year: 2018
  ident: 2282_CR32
  publication-title: Cardiovasc Diabetol
  doi: 10.1186/s12933-018-0773-1
SSID ssj0020766
Score 2.3710046
Snippet Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often...
Background and Aim Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart...
Abstract Background and Aim Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 294
SubjectTerms Aged
Analysis
Antihypertensive drugs
Antilipemic agents
Canada
Cholesterol
Cholesterol - blood
Cholesterol, HDL - blood
Complications and side effects
Female
Health aspects
Heart
Heart enlargement
Heart failure
Heart failure (HF)
Heart Failure - blood
Heart Failure - complications
Heart Failure - mortality
Humans
Hypertension
Hypertension - blood
Hypertension - complications
Hypertrophy, Left Ventricular - blood
Left ventricular hypertrophy (LVH)
Male
Medical research
Medicine, Experimental
Middle Aged
Mortality
Physiological aspects
Prognosis
Proportional Hazards Models
Prospective Studies
Remnant cholesterol (RC)
Risk Factors
ROC Curve
Taiwan
Triglycerides
Triglycerides - blood
Ventricular Remodeling
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pi9UwEA6yB_EiuuuP6iojiB4kbF-Tpq23p7gswooHF_YWkjRhH7xtpe0e3l_iv-tM2j5eEfTi7b0khTQzmfkmnXzD2FsvS2fSPOdeCsulkBmvitrxoCplsKkIKd0dvvymLq7k1-v8-qDUF-WEjfTA48Kd-VB41Drjpaml9MKW0uGWLGSNjSGPZNvo8-Zgagq1MDpX8xWZUp316NWk5OiPOPG9ZHy3cEORrf9Pm3zglJYJkwce6PwRezhBR1iPU37M7vnmmJ2sGwybb3fwDmIyZzwlP2b3L6dv5ifs1_eOfpNZA6L29tAG6PwtZcAAGb_IldBuAeErbH0YgFIg47mg6eAG49Ru6FqUBpimBsrnatp-08OmmTrHFHiYGFp7oKNdoELZAwSzobT3j2DowflWJ0RO2yfs6vzLj88XfCrHwF0u1MBDVgdjpEOMKLPC5WlweRmqwiLGtCI3SslaWmKQQ1BY28xYn5WqMgihUutcJZ6yo6Zt_HMGofIrxF1V6hGO2VWNf0WVOyERYPrUi4StZuloN3GVU8mMrY4xS6n0KFGNEtVRonqXsA_7Z36OTB1_Hf2JhL4fSSzbsQF1T0-6p_-lewl7TyqjyRbg9JyZrjTgSxKrll6XCGipjHeWsNPFSNzDbtH9ZlY6TV2U-Nb49q7XiL5lKujjZcKejUq4nzNCW1Wg0U1YuVDPxUste5rNTaQQX-F6Y2yfvfgfy_CSPcji1qLCGqfsaOju_CuEaoN9HXflb5OuQK4
  priority: 102
  providerName: Directory of Open Access Journals
Title Predictive value of remnant cholesterol for left ventricular hypertrophy and prognosis in hypertensive patients with heart failure: a prospective study
URI https://www.ncbi.nlm.nih.gov/pubmed/39267042
https://www.proquest.com/docview/3104039901
https://pubmed.ncbi.nlm.nih.gov/PMC11391842
https://doaj.org/article/ef7e832ae4ad44e3b84cdde74d32af56
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ti9QwEA73AuIX0TtfqucSQfSDRLttmrSCyJ7ccQh7HOLCfgtpmtwt7LXa9sD9Jf5dZ9J2ueIh-G3bpEubmck8k0yeIeS15anRYZIwy-Oc8ZhHLJOFYU5kQsMt6UI8Ozw_F2cL_nWZLHfIUO6oH8DmztAO60kt6vX7Xz83n8HgP3mDT8WHBnwW5wy8DUM2l4htdsk-eCaJhjrn212FCGL27rSRFAyAxnI4RHPnf4wclefz_3vWvuW2ximVt3zU6UPyoAeXdNZpwyOyY8sDcjgrIbC-3tA31Kd7-nX0A3Jv3u-qH5LfFzX-xomPIvm3pZWjtb3GHBmKI-TZFKo1BYBL19a1FJMk_cqhrukVRLJ1W1cgL6rLgmLGV1k1q4auyr6xS5KnPYdrQ3Hxl2Ip7ZY6vcLE-I9U44PDuU_qWW8fk8XpyfcvZ6wv2MBMEouWuahwWnMDKJJH0iShM0nqMpkDCs3jRAvBC54jxxzAxiKPdG6jVGQaQFaYG5PFT8heWZX2GaEus1NAZlloAbDl0wIu4ywxMQcIakMbB2Q6SEeZns0ci2qslY9qUqE6iSqQqPISVZuAvNs-86Pj8vhn72MU-rYn8nD7G1V9qXqzVtZJC3OitlwXnNs4T7kBhyF5ATddIgLyFlVGof7C6xndH3qAj0TeLTVLAfJioe8oIEejnmDlZtT8alA6hU2YGlfa6qZRgM95GOP2ZkCedkq4fWcAv0LCtByQdKSeo48at5SrK08yPoXxhug_ev5fg_aC3I-8DWGNjSOy19Y39iWgtjafkF25lBOyf3xyfvFt4tc-Jt48_wBLWUN8
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictive+value+of+remnant+cholesterol+for+left+ventricular+hypertrophy+and+prognosis+in+hypertensive+patients+with+heart+failure%3A+a+prospective+study&rft.jtitle=Lipids+in+health+and+disease&rft.au=Wang%2C+Zeyu&rft.au=Zhu%2C+Zhaoxin&rft.au=Shen%2C+Jianying&rft.au=Zhang%2C+Yan&rft.date=2024-09-12&rft.issn=1476-511X&rft.eissn=1476-511X&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs12944-024-02282-y&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12944_024_02282_y
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-511X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-511X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-511X&client=summon